Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents (Note 7)	$ 3,657.1	$ 2,337.5
Short-term investments (Note 7)	24.2	101.0
Accounts receivable, net of allowances of $25.9 (2020) and $22.4 (2019)	5,875.3	4,547.3
Other receivables	1,053.7	994.2
Inventories (Note 6)	3,980.3	3,190.7
Prepaid expenses and other	2,871.5	2,538.9
Total current assets	17,462.1	13,709.6
Investments (Note 7)	2,966.8	1,962.4
Goodwill (Note 8)	3,766.5	3,679.4
Other intangibles, net (Note 8)	7,450.0	6,618.0
Deferred tax assets (Note 14)	2,830.4	2,572.6
Property and equipment, net (Note 9)	8,681.9	7,872.9
Other noncurrent assets	3,475.4	2,871.2
Total assets	46,633.1	39,286.1
Current Liabilities
Short-term borrowings and current maturities of long-term debt (Note 11)	8.7	1,499.3
Accounts payable	1,606.7	1,405.3
Employee compensation	997.2	915.5
Sales rebates and discounts	5,853.0	4,933.6
Dividends payable	770.6	671.5
Income taxes payable (Note 14)	495.1	160.6
Other current liabilities	2,750.3	2,189.4
Total current liabilities	12,481.6	11,775.2
Other Liabilities
Long-term debt (Note 11)	16,586.6	13,817.9
Accrued retirement benefits (Note 15)	4,094.5	3,698.2
Long-term income taxes payable (Note 14)	3,837.8	3,607.2
Other noncurrent liabilities	1,707.5	1,501.0
Deferred tax liabilities (Note 14)	2,099.9	2,187.5
Total other liabilities	28,326.3	24,811.8
Commitments and Contingencies (Note 16)
Eli Lilly and Company Shareholders' Equity (Notes 12 and 13)
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 957,077 (2020) and 958,056 (2019)	598.2	598.8
Additional paid-in capital	6,778.5	6,685.3
Retained earnings	7,830.2	4,920.4
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 17)	(6,496.4)	(6,523.6)
Cost of common stock in treasury	(55.7)	(60.8)
Total Eli Lilly and Company shareholders' equity	5,641.6	2,606.9
Noncontrolling interests	183.6	92.2
Total equity	5,825.2	2,699.1
Total liabilities and equity	$ 46,633.1	$ 39,286.1